Operator
Good afternoon, ladies and gentlemen, and welcome to the Formycon AG Earnings Call Q1 2026. [Operator Instructions] Let me now turn the floor over to your host, Dr. Stefan Glombitza.
Stefan Glombitza
CEO, COO & Chair of the Executive Board
Yes. Thank you, and good afternoon, good morning, and welcome to everyone joining us today. Earlier today, we published our Q1 results for 2026. And before we move to the presentation, let me highlight just some key takeaways upfront. First of all, our financial performance in the first quarter clearly supports our full year guidance 2026, the year marking our entry into sustainable EBITDA profitability and continued scaling of the business.
In the year-on-year comparison, we delivered significant growth versus the first quarter of 2025, which is underlining both the robustness of our business model and the continued strength of our execution. Second takeaway from an operational perspective, we had a strong start to the year as well, achieving multiple key milestones across all 4 pillars of our Fit for Growth strategy with a key highlight, of course, of positive results from our CYP2D6 study in February. And third, on 15th of May, so just recently, we successfully launched our third pipeline product, CYP203, a biosimilar to Eylea in Europe, an important step in further expanding our commercial platform and another testament of our ability to deliver against our pipeline.
